Resumen de Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial

Jacob M. van Laar, Dominique Farge, Jacob K. Sont, Kamran Naraghi

• Importance High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small phase 2 trials.

  Objective To compare efficacy and safety of HSCT vs 12 successive monthly intravenous pulses of cyclophosphamide.